SISU PHARMA, INC.
EXPLOITING THE STRESS PROTECTION RESPONSE
Sisu Pharma exploits cellular stress by directly targeting the transcription factor Heat Shock Factor 1 (HSF1), the Central Regulator of the heat shock response. Our HSF1 targeting platform (HI-LiTe) is being leveraged to deliver selective HSF1 degraders for oncology. Sisu’s first-in-class compounds demonstrate compelling efficacy in therapy-resistant cancer models where all current treatments fail. The platform provides additional opportunities to develop therapies for use in neurodegenerative conditions and infection, providing a unique approach to treating these devastating diseases.
FOUNDERS AND SCIENTIFIC ADVISORY BOARD
Sisu Pharma is led by a team of world-class scientists with decades of experience and success in basic and translational oncology research and FDA-approved cancer drug development